Publication Information

{'id': 'https://openalex.org/W2363852307', 'doi': None, 'title': 'Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer', 'display_name': 'Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer', 'publication_year': 2012, 'publication_date': '2012-01-01', 'ids': {'openalex': 'https://openalex.org/W2363852307', 'mag': '2363852307'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://en.cnki.com.cn/Article_en/CJFDTOTAL-SYYZ201220053.htm', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764666221', 'display_name': 'Shiyong yixue zazhi', 'issn_l': '1006-5725', 'issn': ['1006-5725'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4361729662', 'host_organization_name': 'Medical Information of Guangdong Province', 'host_organization_lineage': ['https://openalex.org/P4361729662'], 'host_organization_lineage_names': ['Medical Information of Guangdong Province'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5067560223', 'display_name': 'Zhang De-fan', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': 'Zhang De-fan', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5067560223'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 2, 'citation_normalized_percentile': {'value': 0.536833, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 72, 'max': 75}, 'biblio': {'volume': None, 'issue': None, 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9988, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9988, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10696', 'display_name': 'Gastric Cancer Management and Outcomes', 'score': 0.9899, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10202', 'display_name': 'Lung Cancer Diagnosis and Treatment', 'score': 0.9898, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/erlotinib-hydrochloride', 'display_name': 'Erlotinib Hydrochloride', 'score': 0.5448293}], 'concepts': [{'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.98506474}, {'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.98049265}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.7937857}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.77669156}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.6930288}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.6405687}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.6131162}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.5529721}, {'id': 'https://openalex.org/C2909325608', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib Hydrochloride', 'level': 5, 'score': 0.5448293}, {'id': 'https://openalex.org/C2778820342', 'wikidata': 'https://www.wikidata.org/wiki/Q906415', 'display_name': 'Tyrosine-kinase inhibitor', 'level': 3, 'score': 0.48039228}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.42843002}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.3228184}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://en.cnki.com.cn/Article_en/CJFDTOTAL-SYYZ201220053.htm', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764666221', 'display_name': 'Shiyong yixue zazhi', 'issn_l': '1006-5725', 'issn': ['1006-5725'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4361729662', 'host_organization_name': 'Medical Information of Guangdong Province', 'host_organization_lineage': ['https://openalex.org/P4361729662'], 'host_organization_lineage_names': ['Medical Information of Guangdong Province'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.87, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': [], 'abstract_inverted_index': {'Objective': [0], 'To': [1], 'compare': [2], 'the': [3, 36, 40, 47, 67, 83, 109, 113, 132, 145], 'efficacy': [4], 'and': [5, 16, 55, 75, 142], 'safety': [6], 'of': [7, 66, 88, 103], 'epidermal': [8], 'growth': [9], 'factor': [10], 'receptor': [11], 'tyrosine': [12], 'kinase': [13], 'inhibitor': [14], 'gefitinib': [15, 99, 129], 'erlotinib': [17, 92, 122, 143], 'alone': [18], 'as': [19], 'a': [20], 'second': [21], 'line': [22], 'treatment': [23, 49, 140], 'for': [24, 50], 'patients': [25, 42, 117, 135], 'with': [26, 118, 136], 'advanced': [27, 133], 'non-small': [28], 'cell': [29], 'lung': [30], 'cancer(NSCLC)': [31], 'who': [32, 43], 'were': [33, 44, 70, 78, 105], 'failed': [34, 45], 'in': [35, 46, 91, 98, 116, 121, 128], 'first-line': [37, 48, 138], 'chemotherapy.Methods': [38], 'Among': [39], '83': [41], 'NSCLC,41': [51], 'received': [52, 57], 'gefitinib(gefitinib': [53], 'group)': [54], '42': [56], 'erlotinib(erlotinib)': [58], 'therapy.The': [59], 'efficacy,progression-free': [60], 'survival': [61, 63, 114], 'time(PFS),median': [62], 'time(MST),and': [64], 'toxicity': [65], 'two': [68, 84, 110], 'groups': [69], 'compared.Results': [71], 'The': [72], 'median': [73, 76], 'PFS': [74], 'OS': [77], 'not': [79], 'significantly': [80, 106], 'different': [81, 107], 'between': [82, 108], 'groups(P': [85, 111], '0.05).The': [86], 'rate': [87], 'adverse': [89], 'events': [90], 'group': [93, 123], 'was': [94, 124], 'higher': [95], 'than': [96, 126], 'that': [97, 127], 'group.The': [100], 'histological': [101], 'types': [102], 'tumor': [104], '0.05),and': [112], 'time': [115], 'squamous': [119], 'carcinoma': [120], 'longer': [125], 'group.Conclusion': [130], 'In': [131], 'NSCLC': [134], 'standard': [137], 'chemotherapy': [139], 'failure,gefitinib': [141], 'had': [144], 'similar': [146], 'overall': [147], 'efficacy.': [148]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2363852307', 'counts_by_year': [{'year': 2017, 'cited_by_count': 2}], 'updated_date': '2024-12-14T09:44:24.770786', 'created_date': '2016-06-24'}